

OCT 8 2003

JC26

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission


23

Application Number	10/623,371
Filing Date	July 18, 2003
First Named Inventor	Karen L. FEARON
Art Unit	1645
Examiner Name	Not Yet Assigned
Attorney Docket Number	377882002021

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement (3 pages) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form PTO-1449 (19 pages) Return receipt postcard
Remarks		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual name	MORRISON & FOERSTER LLP (Customer No. 25226) Randolph Ted Apple - 36,429	
Signature		
Date	12/3/03	

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 12/3/03


Signature:  (Conchita Picazo)



PATENT
Docket No. 377882002021

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on December 3, 2003.


Conchita Picazo

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Karen L. FEARON et al.

Serial No.: 10/623,371

Filing Date: July 18, 2003

For: CHIMERIC IMMUNOMODULATORY
COMPOUNDS AND METHODS OF
USING THE SAME - IV

Examiner: Not Yet Assigned

Group Art Unit: 1645

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents cited in the attached Form PTO-1449 were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related application Serial Number 10/176,883, filed June 21, 2002, and, accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R. §1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

This Information Disclosure Statement is submitted:

- With the application; accordingly, no fee or separate requirements are required.
- Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114.
- Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - A fee is required. A check in the amount of __ is enclosed.
 - A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.
- After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of __ is enclosed.
 - A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.


The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 377882002021. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: 12/17/03

Respectfully submitted,

By:



Randolph Ted Apple
Registration No. 36,429

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5933
Facsimile: (650) 494-0792

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i> 	Docket Number 377882002021		Application Number 10/623,371
	Applicant Karen L. FEARON et al.		
	Filing Date July 18, 2003	Group Art Unit 1645	
	Mailing Date December 3, 2003		


U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	07/03/1984	4,458,066	Caruthers et al.			
	2.	05/06/1986	4,587,329	Tomalia et al.			
	3.	03/17/1987	4,650,675	Borel et al.			
	4.	07/18/1989	4,849,513	Smith et al.			
	5.	03/20/1990	4,910,300	Urdea et al.			
	6.	08/14/1990	4,948,882	Ruth			
	7.	05/14/1991	5,015,733	Smith et al.			
	8.	03/03/1992	5,093,232	Urdea et al.			
	9.	06/02/1992	5,118,800	Smith et al.			
	10.	06/02/1992	5,118,802	Smith et al.			
	11.	06/23/1992	5,124,246	Urdea et al.			
	12.	11/10/1992	5,162,515	Conrad et al.			
	13.	12/15/1992	5,171,264	Merrill			
	14.	08/16/1994	5,338,532	Tomalia et al.			
	15.	02/21/1995	5,391,723	Priest			
	16.	09/26/1995	5,453,496	Caruthers et al.			
	17.	10/24/1995	5,460,831	Kossovsky et al.			
	18.	01/16/1996	5,484,596	Hanna, Jr. et al.			
	19.	09/03/1996	5,552,391	Coutts et al.			
	20.	05/06/1997	5,627,025	Steinman et al.			
	21.	09/02/1997	5,663,153	Hutcherson et al.			
	22.	10/07/1997	5,674,683	Kool			
	23.	10/21/1997	5,679,555	Goodchild et al.			
	24.	03/03/1998	5,723,335	Hutcherson et al.			
	25.	08/18/1998	5,795,582	Wright			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i> 		Docket Number 377882002021	Application Number 10/623,371
		Applicant Karen L. FEARON et al.	
		Filing Date July 18, 2003	Group Art Unit 1645
		Mailing Date December 3, 2003	

	26.	12/15/1998	5,849,719	Carson et al.			
	27.	06/15/1999	5,912,332	Agrawal et al.			
	28.	09/07/1999	5,948,648	Khan et al.			
	29.	02/29/2000	6,031,091	Arnold, Jr. et al.			
	30.	07/18/2000	6,090,791	Sato et al.			
	31.	09/12/2000	6,117,657	Usman et al.			
	32.	09/26/2000	60/235,452	Agrawal			
	33.	09/26/2000	60/235,453	Agrawal			
	34.	10/03/2000	6,127,173	Eckstein et al.			
	35.	11/15/2000	09/712,898	Kandimalla et al.			
	36.	12/05/2000	6,156,501	McGall et al.			
	37.	12/12/2000	6,160,103	Marchand et al.			
	38.	01/16/2001	6,174,872	Carson et al.			
	39.	01/23/2001	6,177,414	Tomalia et al.			
	40.	02/06/2001	6,183,959	Thompson			
	41.	02/27/2001	6,194,388	Krieg et al.			
	42.	03/27/2001	6,207,646	Krieg et al.			
	43.	04/10/2001	6,214,806	Krieg et al.			
	44.	04/17/2001	6,218,371	Krieg et al.			
	45.	05/29/2001	6,239,116	Krieg et al.			
	46.	01/15/2002	6,339,068	Krieg et al.			
	47.	06/18/2002	6,406,705	Davis et al.			
	48.	07/30/2002	6,426,334	Agrawal et al.			
	49.	07/30/2002	6,426,336	Carson et al.			
	50.	08/06/2002	6,429,199	Krieg et al.			
	51.	09/19/2002	2002/0132995	Agrawal et al.			
	52.	09/26/2002	2002/0137714	Kandimalla et al.			
	53.	11/05/2002	6,476,000	Agrawal			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i> DEC 08 2003 JC28 <small>PATENT & TRADEMARK OFFICE</small>	Docket Number 377882002021		Application Number 10/623,371
	Applicant Karen L. FEARON et al.		
	Filing Date July 18, 2003	Group Art Unit 1645	
	Mailing Date December 3, 2003		


	54.	02/25/2003	6,524,613	Steer et al.			
--	-----	------------	-----------	--------------	--	--	--

FOREIGN PATENT DOCUMENTS

	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	55.	04/26/1989	EP 0 313 219	EPO			
	56.	01/29/1992	EP 0 468 520	EPO			
	57.	03/23/1989	WO 89/02439	WIPO			
	58.	07/25/1991	WO 91/10426	WIPO			
	59.	02/04/1993	WO 93/02093	WIPO			
	60.	03/16/1995	WO 95/07073	WIPO			
	61.	12/19/1996	WO 96/40197	WIPO			
	62.	02/01/1996	WO 96/02555	WIPO			
	63.	08/07/1997	WO 97/28259	WIPO			
	64.	12/11/1997	WO 97/46251	WIPO			
	65.	04/23/1998	WO 98/16247	WIPO			
	66.	05/07/1998	WO 98/18810	WIPO			
	67.	09/03/1998	WO 98/37919	WIPO			
	68.	09/17/1998	WO 98/40100	WIPO			
	69.	11/26/1998	WO 98/52581	WIPO			
	70.	11/26/1998	WO 98/52962	WIPO			
	71.	12/10/1998	WO 98/55495	WIPO			
	72.	12/10/1998	WO 98/55609	WIPO			
	73.	03/11/1999	WO 99/11275	WIPO			
	74.	05/14/1999	WO 99/22770	WIPO			
	75.	07/08/1999	WO 99/33488	WIPO			
	76.	07/08/1999	WO 99/33868	WIPO			
	77.	09/16/1999	WO 99/45964	WIPO			

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.
--

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>  <small>PATENT & TRADEMARK OFFICE</small>	Docket Number 377882002021		Application Number 10/623,371
	Applicant Karen L. FEARON et al.		
	Filing Date July 18, 2003	Group Art Unit 1645	
	Mailing Date December 3, 2003		

	78.	10/14/1999	WO 99/51259	WIPO				
	79.	11/11/1999	WO 99/56755	WIPO				
	80.	11/18/1999	WO 99/58118	WIPO				
	81.	12/02/1999	WO 99/61056	WIPO				
	82.	12/09/1999	WO 99/62923	WIPO				
	83.	02/10/2000	WO 00/06588	WIPO				
	84.	03/30/2000	WO 00/16804	WIPO				
	85.	04/20/2000	WO 00/21556	WIPO				
	86.	06/15/2000	WO 00/34231	WIPO				
	87.	06/15/2000	WO 00/34296	WIPO				
	88.	09/21/2000	WO 00/54803	WIPO				
	89.	10/19/2000	WO 00/61151	WIPO				
	90.	11/09/2000	WO 00/67023	WIPO				
	91.	11/16/2000	WO 00/67787	WIPO				
	92.	12/14/2000	WO 00/75105	WIPO				
	93.	02/22/2001	WO 01/12223	WIPO				
	94.	02/22/2001	WO 01/12804	WIPO				
	95.	03/08/2001	WO 01/15726	WIPO				
	96.	04/05/2001	WO 01/22972	WIPO				
	97.	04/05/2001	WO 01/22990	WIPO				
	98.	05/25/2001	WO 01/35991	WIPO				
	99.	06/28/2001	WO 01/45750	WIPO				
	100.	07/19/2001	WO 01/51500	WIPO				
	101.	08/02/2001	WO 01/54720	WIPO				
	102.	08/02/2001	WO 01/55341	WIPO				
	103.	08/02/2001	WO 01/55370	WIPO				
	104.	08/30/2001	WO 01/62207	WIPO				
	105.	09/20/2001	WO 01/68077	WIPO				

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449				Docket Number 377882002021	Application Number 10/623,371		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Applicant			
				Karen L. FEARON et al.			
				Filing Date July 18, 2003	Group Art Unit 1645		
				Mailing Date December 3, 2003			



106.	09/20/2001	WO 01/68078	WIPO				
107.	09/20/2001	WO 01/68103	WIPO				
108.	09/20/2001	WO 01/68116	WIPO				
109.	09/20/2001	WO 01/68117	WIPO				
110.	09/20/2001	WO 01/68143	WIPO				
111.	09/20/2001	WO 01/68144	WIPO				
112.	10/04/2001	WO 01/72123	WIPO				
113.	10/18/2001	WO 01/76642	WIPO				
114.	11/08/2001	WO 01/83503	WIPO				
115.	12/13/2001	WO 01/93902	WIPO				
116.	02/07/2002	WO 02/09766	WIPO				
117.	04/04/2002	WO 02/26757	WIPO				
118.	04/04/2002	WO 02/27315	WIPO				
119.	07/04/2002	WO 02/052002	WIPO				
120.	09/06/2002	WO 02/069369	WIPO				
121.	09/26/2002	WO 02/074922	WIPO				
122.	05/01/2003	WO 03/035836	WIPO				
123.	07/17/2003	WO 03/057822	WIPO				

Ref. No.	Title
124.	Agrawal, S. and Kandimalla, E.R. et al. (1986). "Efficient Methods for Attaching Non-Radioactive Labels to the 5' ends of Synthetic Oligodeoxyribonucleotides," <i>Nucleic Acids Res.</i> 14(15):6227-6245.
125.	Agrawal, S. and Kandimalla, E.R. (2001). "Antisense and/or Immunostimulatory Oligonucleotide," <i>Current Cancer Drug Target</i> 1(3):197-209.
126.	Agrawal, S. (2002). "Medicinal Chemistry and Therapeutic Potential of CpG DNA," <i>Trends In Molecular Medicine</i> 8(3):114-121.
127.	Ahmeida, E.T.S. Ben et al. (1993). "Immunopotentiation of Local and Systemic Humoral Immune Responses by ISCOMs, Liposomes and FCA: Role in Protection Against Influenza A in Mice," <i>Vaccine</i> 11(13):1302-1309.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
pa- 833912 PTO/SB/ 08 (2-92)	
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number 377882002021	Application Number 10/623,371
		Applicant	Karen L. FEARON et al.
		Filing Date July 18, 2003	Group Art Unit 1645
		Mailing Date December 3, 2003	

O 1 2 E
DEC 0 8 2003
JC24
PATENT & TRADEMARK OFFICE

	128.	Altmann, S. et al. (1995). "NMR Studies of DNA Duplexes Singly Cross-Linked by Different Synthetic Linkers," <i>Nucleic Acids Res.</i> 23(23):4827-4835.
	129.	Aramaki, Yukihito et al. (1995). "Interferon- γ Inductive Effect of Liposomes as an Immunoadjuvant," <i>Vaccine</i> 13(18):1809-1814.
	130.	Asanuma, H. et al. (1995). "Cross-Protection Against Influenza Virus Infection in Mice Vaccinated by Combined Nasal-Subcutaneous Administration," <i>Vaccine</i> 13(1):3-5.
	131.	Asensio, J. L. et al. (1998). "Comparison of the Solution Structures of Intramolecular DNA Triple Helices Containing Adjacent and Non-Adjacent CG-C ⁺ Triplets," <i>Nucleic Acids Res.</i> 26(16):3677-3686.
	132.	Atherton, E. et al. (July 1981). "Synthesis of a 21-Residue Fragment of Human Proinsulin by the Polyamide Solid Phase Method," <i>Hoppe-Seylers Z. Physiol. Chem.</i> 362:833-839.
	133.	Ballas, Z. K. et al. (1996). "Induction of NK Activity in Murine and Human Cells by CpG Motifs in Oligodeoxynucleotides and Bacterial DNA," <i>J. Immunol.</i> 157:1840-1845.
	134.	Bartley, J. P. et al. (1997). "Solution Conformation of an Intramolecular DNA Triplex Containing a Nonnucleotide Linker: Comparison with the DNA Duplex," <i>Biochemistry</i> 36(47):14502-14511.
	135.	Beaucage, S. L. (1993). "Oligodeoxyribonucleotide Synthesis," Chapter 3 <i>In Protocols for Oligonucleotides and Analogs, Synthesis and Properties</i> , Sudhir Agrawal, ed., Humana Press, Totowa, NJ., 20:33-61.
	136.	Benoit, R. et al. (1987). "Peptides. Strategies for Antibody Production and Radioimmunoassays," <i>In Neuromethods</i> , Alan A. Boulton et al., eds., Humana Press, Clifton, NJ 6:43-72.
	137.	Bhagat, L. et al. (2003). "CpG Penta and Hexadeoxynucleotides as Potent Immunomodulatory Agents," <i>Biochem. and Biophys. Res. Comm.</i> 300(4):853-861.
	138.	Bischoff, R. et al. (1987). "Introduction of 5'-Terminal Functional Groups into Synthetic Oligonucleotides for Selective Immobilization," <i>Anal. Bioch.</i> 164:336-344.
	139.	Blanks, R. and McLaughlin, L.W. (1988). "An Oligodeoxynucleotide Affinity Column for the Isolation of Sequence Specific DNA Binding Proteins," <i>Nucleic Acids Res.</i> 16(21):10283-10299.
	140.	Bohle, B. et al. (1999). "Oligodeoxynucleotides Containing CpG Motifs Induce IL-12, IL-18, and IFN- γ Production in Cells from Allergic Individuals and Inhibit IgE Synthesis <i>In Vitro</i> ," <i>Eur. J. Immunol.</i> 29:2344-2353.
	141.	Borel, H. and Borel, Y. (1990). "A Novel Technique to Link Either Proteins or Peptides to Gammaglobulin to Construct Tolerogens," <i>Immunol. Methods</i> 126:159-168.
	142.	Borel, Y. et al. (1995). "Food Allergens Transformed Into Tolerogens," <i>Int. Arch. Allergy Immunol.</i> 107:264-267
	143.	Borel, Y. et al. (1996). "Parenteral and Oral Administation of Tolerogens: Protein-IgG Conjugates," Volume 778 <i>In Oral Tolerance: Mechanisms and Applications Ann. N.Y. Acad. Sci.</i> pp. 80-87.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number 377882002021	Application Number 10/623,371
		Applicant	Karen L. FEARON et al.
		Filing Date July 18, 2003	Group Art Unit 1645
		Mailing Date December 3, 2003	

*O 1 4 E JCG
DEC 08 2003 9210*
PATENT & TRADEMARK OFFICE

	144.	Boujard, N. et al. (June 1993). "Inhibition of Hormone-Stimulated Steroidogenesis in Cultured Leydig Tumor Cells by a Cholesterol-Linked Phosphorothioate Oligodeoxynucleotide Antisense to Diazepam-Binding Inhibitor," <i>P NAS USA</i> 90:5728-5731.
	145.	Bousquet, Y. et al. (1999). "Molecular Mechanisms of the Adsorption of a Model Protein (Human Serum Albumin) on Poly(Methylidene Malonate 2.1.2) Nanoparticles," <i>Pharm. Res.</i> 16(1):141-147.
	146.	Branda, R. F. et al. (1993). "Immune Stimulation by an Antisense Oligomer Complementary to the <i>rev</i> Gene of HIV-1," <i>Biochem. Pharmacol.</i> 45(10):2037-2043.
	147.	Branda, R. F. et al. (1996). "Amplification of Antibody Production by Phosphorothioate Oligodeoxynucleotides," <i>J. Lab. Clin. Med.</i> 128(3):329-338.
	148.	Braun, R. P. and Lee, J. S. (1988). "Immunogenic Duplex Nucleic Acids are Nuclease Resistant," <i>J. Immunol.</i> 141(6):2084-2089.
	149.	Brazolot-Milan, C. L. et al. (1998). "CpG DNA Can Induce Strong Th1 Humoral and Cell-Mediated Immune Responses Against Hepatitis B Surface Antigen in Young Mice," <i>P NAS USA</i> 95:15553-15558.
	150.	Breiteneder, H. et al. (1989). "The Gene Coding for the Major Birch Pollen Allergen <i>Betv1</i> , is Highly Homologous to a Pea Disease Resistance Response Gene," <i>EMBO J.</i> 8(7):1935-1938.
	151.	Broide, D. et al. (1998). "Immunostimulatory DNA Sequences Inhibit IL-5, Eosinophilic Inflammation, and Airway Hyperresponsiveness in Mice," <i>J. Immunol.</i> 161:7054-7062.
	152.	Broide, D. and Raz, E. (1999). "DNA-Based Immunization for Asthma," <i>Int. Arch. Allergy Immunol.</i> 118:453-456.
	153.	Carson, D. A. and Raz, E. (1997). "Oligonucleotide Adjuvants for T Helper 1 (Th1)-Specific Vaccination," <i>J. Exp. Med.</i> 186(10):1621-1622.
	154.	Chace, J. H. et al. (1997). "Bacterial DNA-Induced NK Cell IFN- γ Production is Dependent on Macrophage Secretion of IL-12," <i>Clin. Immunol. and Immunopathol.</i> 84(2):185-193.
	155.	Chaturvedi, S. et al. (1996). "Stabilization of Triple-Stranded Oligonucleotide Complexes: Use of Probes Containing Alternating Phosphodiester and Stereo-Uniform Cationic Phosphoramidate Linkages," <i>Nucleic Acids Res.</i> 24(12):2318-2323.
	156.	Chavany, C. et al. (1992). "Polyalkylcyanoacrylate Nanoparticles as Polymeric Carriers for Antisense Oligonucleotides," <i>Pharm. Res.</i> 9(4):441-449.
	157.	Chavany, C. et al. (1994). "Adsorption of Oligonucleotides onto Polyisohexylcyanoacrylate Nanoparticles Protects Them Against Nucleases and Increases Their Cellular Uptake," <i>Pharm. Res.</i> 11(9):1370-1378.
	158.	Chem Genes Corporation Bio Technology Products & Manufacturer of DNA-RNA Intermediates Section 10: Chromophores and Ligands

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number 377882002021	Application Number 10/623,371
		Applicant	Karen L. FEARON et al.
		Filing Date July 18, 2003	Group Art Unit 1645
		Mailing Date December 3, 2003	

O 1 & E
DEC 08 2003 825
PATENTS TRADEMARK OFFICE

159.	Chen, Z. et al. (1999). "Enhanced Protection Against a Lethal Influenza Virus Challenge by Immunization with Both Hemagglutinin- and Neuraminidase-Expressing DNAs," <i>Vaccine</i> 17:653-659.
160.	Cho, H. J. et al. (May 2000). "Immunostimulatory DNA-Based Vaccines Induce Cytotoxic Lymphocyte Activity by a T-Helper Cell-Independent Mechanism," <i>Nature Biotechnol.</i> 18:509-514.
161.	Chu, R. S. et al. (November 1997). "CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity," <i>J. Exp. Med.</i> 186(10):1623-1631.
162.	Cload, S. T. and Schepartz, A. (1991). "Polyether Tethered Oligonucleotide Probes," <i>J. Am. Chem. Soc.</i> 113(16):6324-6326.
163.	Coligan, J. E. et al., eds. (1998). <u>Current Protocols in Immunology</u> , Volume 1, John Wiley & Sons, Inc: pp. 1-9
164.	Connolly, B. A. (1985). "Chemical Synthesis of Oligonucleotides Containing a Free Sulphydryl Group and Subsequent Attachment of Thiol Specific Probes," <i>Nucleic Acids Res.</i> 13(12):4485-4502.
165.	Connolly, B. A. (1987). "The Synthesis of Oligonucleotides Containing a Primary Amino Group at the 5'-Terminus," <i>Nucleic Acids Res.</i> 15(7):3131-3139.
166.	Corey, D. R. and Schultz, P. G. (December 1987). "Generation of a Hybrid Sequence-Specific Single-Stranded Deoxyribonuclease," <i>Science</i> 238:1401-1403.
167.	Cowdery, J. S. et al. (1996). "Bacterial DNA Induces NK Cells to Produce IFN- γ In Vivo and Increases the Toxicity of Lipopolysaccharides," <i>J. Immunol.</i> 156:4570-4575.
168.	Dagneaux, C. et al. (1996). "Parallel and Antiparallel A-A-T Intramolecular Triple Helices," <i>Nucleic Acids. Res.</i> 24(22):4506-4512.
169.	de Martino, M. et al. (August 1999). "Low IgG3 and High IgG4 Subclass Levels in Children with Advanced Human Immunodeficiency Virus-Type 1 Infection and Elevated IgE Levels," <i>Annals of Allergy, Asthma & Immunol.</i> 83:160-164.
170.	Douglas, S. J. et al. (1987). "Nanoparticles in Drug Delivery," <i>Crit. Rev. Ther. Drug. Carrier Syst.</i> 3(3):233-261.
171.	Dumas, V. et al. (1995). "Induction of Tolerance by Administration of Hapten-Immunoglobulin Conjugates is Associated with Decreased IL-2 and IL-4 Production," <i>Arch. Dermatol. Res.</i> 287:123-128.
172.	Durand, M. et al. (1990). "Circular Dichroism Studies of an Oligodeoxyribonucleotide Containing a Hairpin Loop Made of a Hexaethylene Glycol Chain: Conformation and Stability," <i>Nucleic Acids Res.</i> 18(21):6353-6359.
173.	Elkins, K. L. et al. (1999). "Bacterial DNA Containing CpG Motifs Stimulates Lymphocyte-Dependent Protection of Mice Against Lethal Infection with Intracellular Bacteria," <i>J. Immunol.</i> 162:2291-2298.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number 377882002021	Application Number 10/623,371
		Applicant	Karen L. FEARON et al.
		Filing Date July 18, 2003	Group Art Unit 1645
		Mailing Date December 3, 2003	



	174.	Fornadley, J. (1998). "Allergy Immunotherapy," <i>Otolaryngol. Clin. North Am.</i> 31(1):111-127.
	175.	Gais, H-J. et al. (1991). "Structure of a Free, Unassociated Alkyl-Substituted α -Sulfonyl Carbanion: Isolation and X-ray Crystal Structure Analysis of the Inclusive Lithium Cytate ($\text{Me}_2\text{CSO}_2\text{Ph}$) ($\text{Li}^+[\text{2.1.1}]$ cryptand)," <i>J. Am. Chem. Soc.</i> 113:4002-4003.
	176.	Gall, J. G. and Pardue, M. L. (1969). "Formation and Detection of RNA-DNA Hybrid Molecules in Cytological Preparations," <i>PNAS USA</i> 63:378-383.
	177.	Gamper, H. B. et al., (1993). "Facile Preparation of Nuclease Resistant 3' Modified Oligodeoxynucleotides," <i>Nucleic Acids Research</i> 21(1):145-150.
	178.	Gao, H. et al. (1995). "Circularization of Oligonucleotides by Disulfide Bridge Formation," <i>Nucleic Acids Res.</i> 23(11):2025-2029.
	179.	Geoghegan, K. F. and Stroh, J. G. (1992). "Site-Directed Conjugation of Nonpeptide Groups to Peptides and Proteins Via Periodate Oxidation of a 2-Amino Alcohol. Application to Modification at N-Terminal Serine," <i>Bioconjug. Chem.</i> 3(2):138-146.
	180.	Glenn Research Products For DNA Research. "5'-OR 3'-Modifiers" Catalog Table of Contents (page 1) and pages 27-29.
	181.	Glen Research, 2000 Catalog, "Spacer Modifiers, Dendrimers" located at <www.glenresearch.com>, Table of Content, pages 35-36.
	182.	Gnanou, Y. et al. (1988). "Synthesis of Star-Shaped Poly(ethylene oxide)," <i>Makromol. Chem.</i> 189:2885-2892.
	183.	Godard, G. et al. (1995). "Antisense Effects of Cholesterol-Oligodeoxynucleotide Conjugates Associated with Poly(Alkylcyanoacrylate) Nanoparticles," <i>Eur. J. Biochem.</i> 232:404-410.
	184.	Goodchild, J. (May/June 1990). "Conjugates of Oligonucleotides and Modified Oligonucleotides: A Review of Their Synthesis and Properties," <i>Bioconjug. Chem.</i> 1(3):165-187.
	185.	Govorkova, E. A. and Smirnov, Y. A. (1997). "Cross-Protection of Mice Immunized with Different Influenza A (H2) Strains and Challenged with Viruses of the Same HA Subtype," <i>Acta Virol.</i> 41:251-257.
	186.	Grabarek, Z. and Gergely, J. (1990). "Zero-Length Crosslinking Procedure with the Use of Active Esters," <i>Anal. Biochem.</i> 185:131-135.
	187.	Gramzinski, R. A. et al. (February 1998). "Immune Response to a Hepatitis B DNA Vaccine in <i>Aotus</i> Monkeys: A Comparison of Vaccine Formulation, Route, and Method of Administration," <i>Mol. Med.</i> 4:109-118.
	188.	Granoff, D. M. et al. (1993). "Effect of Immunity to the Carrier Protein on Antibody Responses to <i>Haemophilus Influenzae</i> Type B Conjugate Vaccines," <i>Vaccine</i> 11: Suppl. 1:46-51.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
pa- 833912 PTO/SB/ 08 (2-92)	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number 377882002021	Application Number 10/623,371
		Applicant	Karen L. FEARON et al.
		Filing Date July 18, 2003	Group Art Unit 1645
		Mailing Date December 3, 2003	

OIC E
DEC 08 2003
SC28
PATENT & TRADEMARK OFFICE

	189.	Hagiwara, A. and Takahashi, T. et al. (1987). "A New Drug-Delivery-System of Anticancer Agents: Activated Carbon Particles Adsorbing Anticancer Agents," <i>In Vivo</i> 1:241-252.
	190.	Haralambidis, J. et al. (1990b). "The Preparation of Polyamide-Oligonucleotide Probes Containing Multiple Non-Radioactive Labels," <i>Nucleic Acids Res.</i> 18(3):501-505.
	191.	Haralambidis, J. et al. (1990a). "The Synthesis of Polyamide-Oligonucleotide Conjugate Molecules," <i>Nucleic Acids Res.</i> 18(3):493-499.
	192.	Hartmann, G. et al. (2000). "Delineation of a CpG Phosphorothioate Oligodeoxynucleotide for Activating Primate Immune Responses In Vitro and In Vivo," <i>J. Immunol.</i> 164(3):1617-1624.
	193.	Hendry, P et al. (1994). "Using Linkers to Investigate the Spatial Separation of the Conserved Nucleotides A ₉ and G ₁₂ in the Hammerhead Ribozyme," <i>Biochimica et Biophysica Acta</i> 1219:405-412.
	194.	Horner, A. A. et al. (1998). "Immunostimulatory DNA is a Potent Mucosal Adjuvant," <i>Cell. Immunol.</i> 190:77-82.
	195.	Inman, J. K. (February 1975). "Thymus-Independent Antigens: The Preparation of Covalent, Hapten-Ficoll Conjugates," <i>J. Immunol.</i> 114(2,Part 1):704-709.
	196.	Iyer, R. P. et al. (1990). "The Automated Synthesis of Sulfur-Containing Oligodeoxyribonucleotides Using 3 H-1,2-Benxodithiol-3-one 1,1-Dioxide as a Sulfur-Transfer Reagent," <i>J. Org. Chem.</i> 55(15):4693-4699.
	197.	Jäger, A. et al. (1988). "Oligonucleotide N-Alkylphosphoramidates: Synthesis and Binding to Polynucleotides," <i>Biochem.</i> 27(19):7237-7246.
	198.	Jakob, T. et al. (1998). "Activation of Cutaneous Dendritic Cells by CpG-Containing Oligodeoxynucleotides: A Role for Dendritic Cells in the Augmentation of Th1 Responses by Immunostimulatory DNA," <i>J. Immunol.</i> 161:3042-3049.
	199.	Jäschke, A. et al. (1993). "Automated Incorporation of Polyethylene Glycol into Synthetic Oligonucleotides," <i>Tetrahedron Letters</i> 34(2):301-304.
	200.	Kandimalla, E. R. et al. (2001). "Effect of Chemical Modifications of Cytosine and Guanine in a CpG-Motif of Oligonucleotides: Structure-Immunostimulatory Activity Relationships," <i>Bioorg. Med. Chem.</i> 9:807-813.
	201.	Kandimalla, E. R. et al. (2002). "Conjugation of Ligands at the 5'-end of CpG DNA Affects Immunostimulatory Activity," <i>Bioconj. Chem.</i> 13(5):966-974.
	202.	Kandimalla, E. R. (2002). "Towards Optimal Design of Second-Generation Immunodulatory Oligonucleotides," <i>Curr. Opin. Mol. Therap.</i> 4(2):122-129.
	203.	Kandimalla, E. R. et al. (2003). "Divergent Synthetic Nucleotide Motif Recognition Pattern: Design and Development of Potent Immunomodulatory Oligodeoxyribonucleotide Agents With Distinct Cytokine Induction Profiles," <i>Nucleic Acids Research</i> 31(9):2393-2400.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number 377882002021	Application Number 10/623,371
		Applicant	Karen L. FEARON et al.
		Filing Date July 18, 2003	Group Art Unit 1645
		Mailing Date December 3, 2003	

OIC JC2
DEC 08 2003
PATENT & TRADEMARK OFFICE USA

	204.	Kandimalla, E. R. et al. (2003). "Secondary Structures in CpG Oligonucleotides Affect Immunostimulatory Activity," <i>Biochemical and Biophysical Research Communications</i> 306:948-953.
	205.	Kataoka, T. et al. (1992). "Antitumor Activity of Synthetic Oligonucleotides with Sequences from cDNA Encoding Proteins of <i>Mycobacterium Bovis</i> BCG," <i>Jpn. J. Cancer Res.</i> 83:244-247.
	206.	Kessler, C. (December 1992). "Nonradioactive Labeling Methods for Nucleic Acids," Chapter 2 <i>In Nonisotopic DNA Probe Techniques</i> , Larry J. Kricka, ed., Academic Press, Inc.: pp. 29-92.
	207.	Kikuta, K. et al. (1990). "Cross-Protection Against Influenza B Type Virus Infection by Intranasal Inoculation of the HA Vaccines Combined with Cholera Toxin B Subunit," <i>Vaccine</i> 8:595-599.
	208.	Kimura, Y. et al. (1994). "Binding of Oligoguanosine to Scavenger Receptors is Required for Oligonucleotides to Augment NK Cell Activity and Induce IFN," <i>J. Biochem.</i> 116(5):991-994.
	209.	Kline, J. N. et al. (March 1997). "Immune Redirection by CpG Oligonucleotides Conversion of a Th2 Response to a Th1 Response in a Murine Model of Asthma," <i>J. Invest. Med.</i> 45(3):282A.
	210.	Klinman, D. M. et al. (April 1996). "CpG Motifs Present in Bacterial DNA Rapidly Induce Lymphocytes to Secrete Interleukin 6, Interleukin 12, and Interferon γ ," <i>PNAS USA</i> 93:2879-2883.
	211.	Klinman, D. M. et al. (1997). "Contribution of CpG Motifs to the Immunogenicity of DNA Vaccines," <i>J. Immunol.</i> 158:3635-3639.
	212.	Kodihalli, S. et al. (May 1997). "Cross-Protection Among Lethal H5N2 Influenza Viruses Induced by DNA Vaccine to the Hemagglutinin," <i>J. Virol.</i> 71(5):3391-3396.
	213.	Kovarik, J. et al. (1999). "CpG Oligodeoxynucleotides Can Circumvent the Th2 Polarization of Neonatal Responses to Vaccines But May Fail to Fully Redirect Th2 Responses Established by Neonatal Priming," <i>J. Immunol.</i> 162:1611-1617.
	214.	Kremsky, J. N. et al. (1987). "Immobilization of DNA via Oligonucleotides Containing an Aldehyde or Carboxylic Acid Group at the 5' Terminus," <i>Nucleic Acids Res.</i> 15(7):2891-2909.
	215.	Krieg, A. M. et al. (October 1989). "A Role for Endogenous Retroviral Sequences in the Regulation of Lymphocyte Activation," <i>J. Immunol.</i> 143(6):2448-2451.
	216.	Krieg, A. M. et al. (April 1995). "CpG Motifs in Bacterial DNA Trigger Direct B-Cell Activation," <i>Nature</i> 374:546-549.
	217.	Krieg, A. M. (February 1996). "Lymphocyte Activation by CpG Dinucleotide Motifs in Prokaryotic DNA," <i>Trends Microbiol.</i> 4(2):73-77.
	218.	Krieg, A. M. et al. (1996). "Oligodeoxynucleotide Modifications Determine the Magnitude of B Cell Stimulation by CpG Motifs," <i>Antisense Nucleic Acid Drug Dev.</i> 6:133-139.
	219.	Krieg, A. M. (1998). "Leukocyte Stimulation by Oligodeoxynucleotides," Chapter 24 <i>In Applied Antisense Oligonucleotide Technology</i> , C.A. Stein and Arthur M. Krieg, eds., Wiley-Liss, Inc.: pp. 431-448.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number 377882002021	Application Number 10/623,371
		Applicant	Karen L. FEARON et al.
		Filing Date July 18, 2003	Group Art Unit 1645
		Mailing Date December 3, 2003	



220.	Krieg, A. M. et al. (January 1998a). "The Role of CpG Dinucleotides in DNA Vaccines," <i>Trends Microbiol.</i> 6(1):23-27.
221.	Krieg, A. M. et al. (1998b). "CpG DNA Induces Sustained IL-12 Expression In Vivo and Resistance to <i>Listeria Monocytogenes</i> Challenge," <i>J. Immunol.</i> 161:2428-2434.
222.	Krieg, A. M. et al. (October 1998c). "Sequence Motifs in Adenoviral DNA Block Immune Activation by Stimulatory CpG Motifs," <i>PNAS USA</i> 95:12631-12636.
223.	Krieg, A. M. (February 1999). "CpG DNA: A Novel Immunomodulator," <i>Trends Microbiol.</i> 7(2):64-65.
224.	Lambert, G. et al. (1998). "Effect of Polyisobutylcyanoacrylate Nanoparticles and Lipofectin® Loaded with Oligonucleotides on Cell Viability and PKC α Neosynthesis in HepG2 Cells," <i>Biochimie</i> 80:969-976.
225.	Langenberg, A. G. M. (June 1995). "A Recombinant Glycoprotein Vaccine for Herpes Simplex Type 2: Safety and Efficacy," <i>Ann. Intern. Med.</i> 122(12):889-898.
226.	Latimer, L. J. P. et al. (1995). "Specificity of Monoclonal Antibodies Produced Against Phosphorothioate and Ribo Modified DNAs," <i>Mol. Immunol.</i> 32(14/15):1057-1064.
227.	Lea, I. A. et al., (1996). "Cloning and Sequencing of cDNAs Encoding the Human Sperm Protein, Sp17," <i>Biochim. et Biophys. Acta</i> 1307:263-266.
228.	Leclerc, C. et al. (1997). "The Preferential Induction of a Th1 Immune Response by DNA-Based Immunization is Mediated by the Immunostimulatory Effect of Plasmid DNA," <i>Cell. Immunol.</i> 179:97-106.
229.	Lee, A. C. J. et al. (1980). "A Method for Preparing β -hCG COOH Peptide-Carrier Conjugates of Predictable Composition," <i>Mol. Immunol.</i> 17:749-756.
230.	Lee, S. W. et al. (October 2000). "Effects of a Hexameric Deoxyriboguanosine Run Conjugation into CpG Oligodeoxynucleotides on Their Immunostimulatory Potentials," <i>J. Immunol.</i> 165(7):3631-3639.
231.	Li, S.F.Y.ed. (1992). "Electrolyte Systems" Chapter 5 In <u>Capillary Electrophoresis, Principles and Practice and Application</u> . Elsevier Science Publishers, Amsterdnam, The Netherlands, pp. 201-206.
232.	Liang, H. et al. (1996). "Activation of Human B Cells by Phosphorothioate Oligodeoxynucleotides," <i>J. Clin. Invest.</i> 98(5):1119-1129.
233.	Lipford, G. B. et al. (1997a). "CpG-Containing Synthetic Oligonucleotides Promote B and Cytotoxic T Cell Responses to Protein Antigen: A New Class of Vaccine Adjuvants," <i>Eur. J. Immunol.</i> 27:2340-2344.
234.	Lipford, G. B. et al. (1997b). "Immunostimulatory DNA: Sequence-Dependent Production of Potentially Harmful or Useful Cytokines," <i>Eur. J. Immunol.</i> 27:3420-3426.

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number 377882002021	Application Number 10/623,371
		Applicant Karen L. FEARON et al.	
		Filing Date July 18, 2003	Group Art Unit 1645
		Mailing Date December 3, 2003	

OCT 08 2003
U.S. PATENT & TRADEMARK OFFICE

235.	Liu, H-M. et al. (1998). "Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating Factor," <i>Blood</i> 92(10):3730-3736.
236.	Ma, M. Y-X. et al. (1993). "Design and Synthesis of RNA Miniduplexes via A Synthetic Linker Approach," <i>Biochemistry</i> 32(7):1751-1758.
237.	Ma, M. Y-X. et al. (1993). "Design and Synthesis of RNA Miniduplexes Via A Synthetic Linker Approach.2. Generation of Covalently Closed, Double-Stranded Cyclic HIV-1 TAR RNA Analogs with High Tat-Binding Affinity," <i>Nucleic Acids Res.</i> 21(11):2585-2589.
238.	Macfarlane, D. E. et al. (1997). "Unmethylated CpG-Containing Oligodeoxynucleotides Inhibit Apoptosis in WEHI 231 B Lymphocytes Induced by Several Agents: Evidence for Blockade of Apoptosis at a Distal Signalling Step," <i>Immunology</i> 91:586-593.
239.	Manzel, L. and Macfarlane, D. E. (1999). "Lack of Immune Stimulation by Immobilized CpG-Oligodeoxynucleotide," <i>Antisense Nucl. Acid Drug Dev.</i> 9:459-464.
240.	Martin-Orozco, E. et al. (1999). "Enhancement of Antigen-Presenting Cell Surface Molecules Involved in Cognate Interactions by Immunostimulatory DNA Sequences," <i>Int. Immunol.</i> 11(7):1111-1118.
241.	Matteucci, M. (1997). "Oligonucleotide Analogs: An Overview," In <i>Oligonucleotides as Therapeutic Agents</i> . D.J. Chadwick and G. Cardew, eds., John Wiley and Sons, New York, NY., pp. 5-18.
242.	Mbwuike, I. N. et al. (1994). "Influenza: A Subtype Cross-Protection After Immunization of Outbred Mice with a Purified Chimeric NS ₁ /HA ₂ Influenza Virus Protein," <i>Vaccine</i> 12(14):1340-1348.
243.	McCluskie, M. J. and Davis, H. L. (1998). "CpG DNA is a Potent Enhancer of Systemic and Mucosal Immune Responses Against Hepatitis B Surface Antigen with Intranasal Administration to Mice," <i>J. Immunol.</i> 161:4463-4466.
244.	McCurdy, S. et al. (1991)."Deoxyoligonucleotides with Inverted Polarity: Synthesis and Use in Triple-Helix Formation," <i>Nucleosides & Nucleotides</i> 10(1-3):287-290.
245.	Miller, P. S. et al. (1971). "Syntheses and Properties of Adenine and Thymine Nucleoside Alkyl Phosphotriesters, the Neutral Analogs of Dinucleoside Monophosphates," <i>JACS</i> 93(24):6657-6665.
246.	Mitragotri, S. et al. (August 1995). "Ultrasound-Mediated Transdermal Protein Delivery," <i>Science</i> 269:850-853.
247.	Mojcik, C. F. et al. (May 1993). "Administration of a Phosphorothioate Oligonucleotide Antisense to Murine Endogenous Retroviral MCF Env Causes Immune Effects <i>In Vivo</i> in a Sequence-Specific Manner," <i>Clin. Immunol. and Immunopathol.</i> 67(2):130-136.
248.	Moldoveanu, Z. et al. (1998). "CpG DNA, A Novel Immune Enhancer for Systemic and Mucosal Immunization with Influenza Virus," <i>Vaccine</i> 16(11/12):1216-1224.
249.	Nelson, P. S. et al. (1989). "Bifunctional Oligonucleotide Probes Synthesized Using a Novel CPG Support are able to Detect Single Base Pair Mutations," <i>Nucleic Acids Res.</i> 17(18):7187-7194.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.


Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number 377882002021	Application Number 10/623,371
		Applicant	Karen L. FEARON et al.
		Filing Date July 18, 2003	Group Art Unit 1645
		Mailing Date December 3, 2003	

DEC 06 2013
PARENT & TRADEMARK OFFICE
C 14 E JC 29

	250.	Nelson, J. S. et al. (1996). "Incorporation of a Non-Nucleotide Bridge into Hairpin Oligonucleotides Capable of High-Affinity Binding to the Rev Protein of HIV-1," <i>Biochemistry</i> 35(16):5339-5344.
	251.	Nelson, J. S. et al. (1997). "N3'→P5' Oligodeoxyribonucleotide Phosphoramidates: A New Method of Synthesis Based on a Phosphoramidite Amine-Exchange Reaction," <i>J. Org. Chem.</i> 62(21):7278-7287.
	252.	O'Shannessy, D. J. and Quarles, R. H. (1985). "Specific Conjugation Reactions of the Oligosaccharide Moieties of Immunoglobulins," <i>J. Applied Biochem.</i> 7:347-355.
	253.	Ono, A. et al. (1991). "DNA Triplex Formation of Oligonucleotide Analogues Consisting of Linker Groups and Octamer Segments That Have Opposite Sugar-Phosphate Backbone Polarities," <i>Biochemistry</i> 30(41):9914-9921.
	254.	Pertmer, T. M. et al. (September 1996). "Influenza Virus Nucleoprotein-Specific Immunoglobulin G Subclass and Cytokine Responses Elicited by DNA Vaccination are Dependent on the Route of Vector DNA Delivery," <i>J. Virol.</i> 70(9):6119-6125.
	255.	Peyrottes, S. et al. (1996). "Oligodeoxynucleoside Phosphoramidates (P-NH ₂): Synthesis and Thermal Stability of Duplexes with DNA and RNA Targets," <i>Nucleic Acids Res.</i> 24(10):1841-1848.
	256.	Pichyangkul, S. et al. (January 2001). "Whole Blood Cultures to Assess the Immunostimulatory Activities of CpG Oligodeoxynucleotides," <i>J. Immunol. Methods</i> 247(1-2):83-94.
	257.	Pierce Enodogen Brands of QB Perbio, Bringing You the Best Life Science Tools for Protein Chemistry Immunology & Proteomics. 2001-2002 Catalog. pg-324-325 and 329.
	258.	Pils, W. and Micura, R. (May 2000). "Flexible Non-Nucleotide Linkers as Loop Replacements in Short Double Helical RNAs," <i>Nucleic Acids Res.</i> 28(9):1859-1863.
	259.	Pisetsky, D. S. and Reich, C. F. (1994). "Stimulation of Murine Lymphocyte Proliferation by a Phosphorothioate Oligonucleotide with Antisense Activity for Herpes Simplex Virus," <i>Life Sci.</i> 54(2):101-107.
	260.	Pisetsky, D. S. et al. (1995). "Immunological Properties of Bacterial DNA," <i>Ann. N.Y. Acad. Sci.</i> 772:152-163.
	261.	Pisetsky, D. S. (January 1996a). "The Immunologic Properties of DNA," <i>J. Immunol.</i> 156(2):421-423.
	262.	Pisetsky, D. S. (October 1996b). "Immune Activation by Bacterial DNA: A New Genetic Code," <i>Immunity</i> 5:303-310.
	263.	Raz, E. et al. (September 1994). "Intradermal Gene Immunization: The Possible Role of DNA Uptake in the Induction of Cellular Immunity to Viruses," <i>PNAS USA</i> 91:9519-9523.
	264.	Raz, E. et al. (May 1996). "Preferential Induction of a Th ₁ Immune Response and Inhibition of Specific IgE Antibody Formation by Plasmid DNA Immunization," <i>PNAS USA</i> 93:5141-5145.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number 377882002021	Application Number 10/623,371
		Applicant	Karen L. FEARON et al.
		Filing Date July 18, 2003	Group Art Unit 1645
		Mailing Date December 3, 2003	



265.	Redford, T. W. et al. (1998). "Cyclosporin A Enhances IL-12 Production by CpG Motifs in Bacterial DNA and Synthetic Oligodeoxynucleotides," <i>J. Immunol.</i> 161:3930-3935.
266.	Rein, D. et al. (1993). "New Developments in Synthesis of Star Polymers with Poly(ethylene oxide) Arms," <i>Acta Polymer</i> 44:225-229.
267.	Reynolds, M. A. et al. (1996). "Antisense Oligonucleotides Containing an Internal , Non-Nucleotied-Based Linker Promote Site-Specific Cleavage of RNA," <i>Nucleic Acids Res.</i> 24(4):760-765.
268.	Rhodes, A. J. and van Rooyen, C. E., eds. (1953). "Fundamental Characteristics and Technical Methods and Apparatus" In <i>Textbook of Virology for Students and Practitioners of Medicine</i> . 2nd ed., Williams and Wilkins Company, Baltimore, MD. pp. 66-69.
269.	Richardson, P. L. and Schepartz, A. (1991). "Tethered Oligonucleotide Probes. A Strategy for the Recognition of Structured RNA," <i>J. Am. Chem. Soc.</i> 113:5109-5111.
270.	Roget, A. et al. (1989). "Synthesis and Use of Labelled Nucleoside Phosphoramidite Building Blocks Bearing a Reporter Group: Biotinyl, Dinitrophenyl, Pyrenyl and Dansyl," <i>Nucleic Acids Res.</i> 17(19):7643-7651.
271.	Romagnani, S. (July 2000). "T-Cell Subsets (Th1 versus Th2)," <i>Ann. Allergy, Asthma, and Immunol.</i> 85(1):9-18.
272.	Roman, M. et al. (August 1997). "Immunostimulatory DNA Sequences Function as T Helper-1-Promoting Adjuvants," <i>Nature Med.</i> 3(8):849-854.
273.	Ruth, J. L. (1991). "Oligodeoxynucleotides with Reporter Groups Attached to the Base," Chapter 11 In <i>Oligonucleotides and Analogues: A Practical Approach</i> , F. Eckstein, ed., IRL Press: pp. 255-282.
274.	Salunkhe, M. et al. (1992). "Control of Folding and Binding of Oligonucleotides by Use of a Nonnucleotide Linker," <i>J. Am. Chem. Soc.</i> 114(23):8768-8772.
275.	Sato, Y. et al. (July 1996). "Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene Immunization," <i>Science</i> 273:352-354.
276.	Scaringe, S. A. et al. (1990). "Chemical Synthesis of Biologically Active Oligoribonucleotides Using β -Cyanoethyl Protected Ribonucleoside Phosphoramidites," <i>Nucleic Acids Res.</i> 18(18):5433-5441.
277.	Schacht, E. et al. (October 1996). "Biomedical Applications of Degradable Polyphosphazenes," <i>Biotechnol. Bioeng.</i> 52:102-108.
278.	Scheerens, H. et al. (2001). "Characterzation of Chemokines and Chemokine Receptors in Two Murine Models of Inflammatory Bowel Disease: IL-10 ^{-/-} Mice and Rag 2 ^{-/-} Mice Reconstituted with CD4 ⁺ CD45RB ^{high} T Cells," <i>Eur. J. Immunol</i> 31:1465-1474.
279.	Scherle, P. A. and Gerhard, W. (October 1986). "Functional Analysis of Influenza Specific- Helper T Cell Clones In Vivo," <i>J. Exp. Med.</i> 164:1114-1128.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
pa- 833912 PTO/SB/ 08 (2-92)	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number 377882002021	Application Number 10/623,371
		Applicant	Karen L. FEARON et al.
		Filing Date July 18, 2003	Group Art Unit 1645
		Mailing Date December 3, 2003	


O 1 & F
DEC 08 2003
PATENT & TRADEMARK OFFICE
U.S. DEPARTMENT OF COMMERCE

	280.	Scherle, P. A. and Gerhard, W. (June 1988). "Differential Ability of B Cells Specific for External vs. Internal Influenza Virus Proteins to Respond to Help from Influenza Virus-Specific T-cell Clones <i>In Vivo</i> ," <i>PNAS USA</i> 85:4446-4450.
	281.	Scheule, R. K. (November 2000). "The Role of CpG Motifs in Immunostimulation and Gene Therapy," <i>Adv. Drug Deliv. Rev.</i> 44(2-3):119-134.
	282.	Schroeder, U. et al. (1998). "Efficacy of Oral Dalargin-Loaded nanoparticle Delivery Across the Blood-Brain Barrier," <i>Peptides</i> 19(4):777-780.
	283.	Schultz, R. G. and Gryaznov, S. M. (July 1996). "Oligo-2'-Fluoro-2'-Deoxynucleotide N3'→P5' Phosphoramidates: Synthesis and Properties," <i>Nucleic Acids Res.</i> 24(15):2966-2973.
	284.	Schwartz, D. A. et al. (1997). "CpG Motifs in Bacterial DNA Cause Inflammation in the Lower Respiratory Tract," <i>J. Clin. Invest.</i> 100(1):68-73.
	285.	Seela, F. and Kaiser, K. (1987). "Oligodeoxyribonucleotides Containing 1,3-Propanediol as Nucleoside Substitute," <i>Nucleic Acids Res.</i> 15(7):3113-3129.
	286.	Shearwater Polymers, Inc. Catalog Polyethylene Glycol Derivatives (1997-1998). Functionalized Biocompatible Polymers for Research and Pharmaceuticals. Star PEGs and Branched PEGs. page 8.
	287.	Shimada, S. et al. (August 1986). "In Vivo Augmentation of Natural Killer Cell Activity with a Deoxyribonucleic Acid Fraction of BCG," <i>Jpn. J. Cancer Res.</i> 77:808-816.
	288.	Sinha, N. D. and Striepeke, S. (1991). "Oligonucleotides with Reporter Groups Attached to the 5'-Terminus," Chapter 8 <i>In Oligonucleotide Analogues: A Practical Approach</i> , F. Eckstein, ed., IRL Press: pp. 185-210.
	289.	Sonehara, K. et al. (1996). "Hexamer Palindromic Oligonucleotides with 5'-CG-3' Motif(s) Induce Production of Interferon," <i>J. Interferon and Cytokine Res.</i> 16:799-803.
	290.	Sparwasser, T. et al. (1997). "Macrophages Sense Pathogens Via DNA Motifs: Induction of Tumor Necrosis Factor-α-Mediated Shock," <i>Eur. J. Immunol.</i> 27:1671-1679.
	291.	Spiegelberg, H.L. et al. (1998). "Inhibition of IgE Formation and Allergic Inflammation by Allergen Gene Immunization and by CpG Motif Immunostimulatory Oligodeoxynucleotides," <i>Allergy</i> 53:93-97.
	292.	Spiegelberg, H. L. et al. (1999). "Inhibition of Allergic Inflammation in the Lung by Plasmid DNA Allergen Immunization," <i>Pediatr. Pulmonol. Suppl.</i> 18:118-121.
	293.	Stacey, K. J. et al. (1996). "Macrophages Ingest and are Activated by Bacterial DNA," <i>J. Immunol.</i> 157:2116-2122.
	294.	Staros, J. V. et al. (1986). "Enhancement by N-Hydroxysulfosuccinimide of Water-Soluble Carbodiimide-Mediated Coupling Reactions," <i>Anal. Biochem.</i> 156:220-222.

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number 377882002021	Application Number 10/623,371
		Applicant	Karen L. FEARON et al.
		Filing Date July 18, 2003	Group Art Unit 1645
		Mailing Date December 3, 2003	



295.	Stein, C. A. and Krieg, A. (1997). "Non-Antisense Effects of Oligodeoxynucleotides," Chapter 11 <i>In Antisense Technology</i> , C. Lichtenstein and W. Nellen, eds., IRL Press: pp.241-264.
296.	Stirchak, E. P. et al. (1989). "Uncharged Stereoregular Nucleic Acid Analogs: 2. Morpholino Nucleoside Oligomers with Carbamate Internucleoside Linkages," <i>Nucleic Acids Res.</i> 17(15):6129-6141.
297.	Takahashi, H. et al. (April 1990). "Induction of CD8 ⁺ Cytotoxic T Cells by Immunization with Purified HIV-1 Envelope Protein in ISCOMs," <i>Nature</i> 344:873-875.
298.	Tamura, S-I. et al. (1992). "Superior Cross-Protective Effect of Nasal Vaccination to Subcutaneous Inoculation with Influenza Hemagglutinin Vaccine," <i>Eur. J. Immunol.</i> 22:477-481.
299.	Tamura, S-I. et al. (1994). "Formulation of Inactivated Influenza Vaccines for Providing Effective Cross-Protection by Intranasal Vaccination in Mice," <i>Vaccine</i> 12(4):310-316.
300.	Tang, J-Y. et al. (2000). "Large-Scale Synthesis of Oligonucleotide Phosphorothioates Usin 3-Amino-1,2,4-Dithiazole-Thione as an Efficient Sulfur-Transfer Reagent," <i>Org. Process Res. Dev.</i> 4(3):194-198.
301.	Thomson, J. B. et al. (1993). "Activity of Hammerhead Ribozymes Containing Non-Nucleotidic Linkers," <i>Nucleic Acids Res.</i> 21(24):5600-5603.
302.	Tokunaga, T. et al. (1992). "Synthetic Oligonucleotides with Particular Base Sequences from the cDNA Encoding Proteins of <i>Mycobacterium Bovis</i> BCG Induce Interferons and Activate Natural Killer Cells," <i>Microbiol. Immunol.</i> 36(1):55-66.
303.	Tomalia, D. A et al. (1990). "Starburst Dendrimers: Molecular-Level Control of Size, Shape, Surface Chemistry, Topology, and Flexibility from Atoms to Macroscopic Matter," <i>Angew Chem. Int. Ed. Engl.</i> 29:138-175.
304.	Tung, C-H. et al. (1991). "Preparation of Oligonucleotide-Peptide Conjugates," <i>Bioconjug. Chem.</i> 2:464-465.
305.	Usman, N. et al. (1987). "Automated Chemical Synthesis of Long Oligoribonucleotides Using 2'-O-Silylated Ribonucleoside 3'-O-Phosphoramidites on Sequence Similar to the 3'-Half Molecule of an <i>Escherichia Coli</i> Formylmethionine tRNA," <i>J. Am. Chem. Soc.</i> 109(25):7845-7854.
306.	Vailes, L. D. et al. (February 1998). "High-Level Expression of Cockroach Allergen, Bla g 4, in <i>Pichia Pastoris</i> ," <i>J. Allergy Clin. Immunol.</i> 101(2 part 1):274-280.
307.	Verthelyi, D. et al. (2001). "Human Peripheral Blood Cells Differentially Recognize and Respond to Two Distinct CpG Motifs," <i>J. Immunol.</i> 166(4):2372-2377.
308.	Walker, P. S. et al. (June 1999). "Immunostimulatory Oligodeoxynucleotides Promote Protective Immunity and Provide Systemic Therapy for Leishmaniasis Via IL-12- and IFN- γ -Dependent Mechanisms," <i>PNAS USA</i> 96(12):6970-6975.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
pa- 833912 PTO/SB/ 08 (2-92)	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number 377882002021	Application Number 10/623,371
		Applicant	Karen L. FEARON et al.
		Filing Date July 18, 2003	Group Art Unit 1645
		Mailing Date December 3, 2003	



	309.	Wang, S. and Kool, E. T. (1994). "Circular RNA Oligonucleotides. Synthesis, Nucleic Acid Binding Properties, and a Comparison with Circular DNAs," <i>Nucleic Acids Res.</i> 22(12):2326-2333.
	310.	Warner, B. D. et al. (1984). "Laboratory Methods: Construction and Evaluation of an Instrument for the Automated Synthesis of Oligodeoxyribonucleotides," <i>DNA</i> 3(5):401-411.
	311.	Watwe, R. M. and Bellare, J. R. (April 1995). "Manufacture of Liposomes: A Review," <i>Current Science</i> 68(7):715-724.
	312.	Weeratna, R. et al. (1998). "Reduction of Antigen Expression from DNA Vaccines by Coadministered Oligodeoxynucleotides," <i>Anti. and Nucleic Acid Drug Develop.</i> 8:351-356.
	313.	Weiner, G. J. et al. (September 1997). "Immunostimulatory Oligodeoxynucleotides Containing the CpG Motif are Effective as Immune Adjuvants in Tumor Antigen Immunization," <i>PNAS USA</i> 94:10833-10837.
	314.	Widhe, M. et al. (1998). "IgG Subclasses in Lyme Borreliosis: A Study of Specific IgG Subclass Distribution in an Interferon- γ -Predominated Disease," <i>Scand. J. Immunol.</i> 47:575-581.
	315.	Williams, J. D. and Hall, K. B. (1996). "Thermodynamic Comparison of the Salt Dependence of Natural RNA Hairpins and RNA Hairpins with Non-Nucleotide Spacers," <i>Biochemistry</i> 35(46):14665-14670.
	316.	Wooldridge, J. E. et al. (April 1997). "Immunostimulatory Oligodeoxynucleotides Containing CpG Motifs Enhance the Efficacy of Monoclonal Antibody Therapy of Lymphoma," <i>Blood</i> 89(8):2994-2998.
	317.	Wyrzkiewicz, T. K. et al. (1994). "Efficiency of Sulfurization in the Synthesis of Oligodeoxyribonucleotide Phosphorothioates Utilizing Various Sulfurizing Reagents," <i>Bioorg. & Med. Chem. Lett.</i> 4(12):1519-1522.
	318.	Yamamoto, S. et al. (June 1992). "Unique Palindromic Sequences in Synthetic Oligonucleotides are Required to Induce INF and Augment INF-Mediated Natural Killer Activity," <i>J. Immunol.</i> 148(12):4072-4076.
	319.	Yamamoto, T. et al. (1994a). "Ability of Oligonucleotides with Certain Palindromes to Induce Interferon Production and Augment Natural Killer Cell Activity is Associated with Their Base Length," <i>Anti. Res. and Develop.</i> 4:119-122.
	320.	Yamamoto, T. et al. (1994b). "Synthetic Oligonucleotides with Certain Palindromes Stimulate Interferon Production of Human Peripheral Blood Lymphocytes <i>In Vitro</i> ," <i>Jpn. J. Cancer Res.</i> 85:775-779.
	321.	Yamana, K. et al. (1999). "Synthesis of Oligonucleotides Containing a New Azobenzene Fragment with Efficient Photoisomerizability," <i>Bioorg. and Med. Chem.</i> 7:2977-2983.
	322.	Yanagawa, H. et al. (February 1988). "Analysis of Superhelical Structures of Nucleic Acid-Lipid Conjugates by Image Processing," <i>Nucleic Acids Symp. Series</i> 19:189-192.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number 377882002021	Application Number 10/623,371
		Applicant	Karen L. FEARON et al.
		Filing Date July 18, 2003	Group Art Unit 1645
		Mailing Date December 3, 2003	

C 1 C PTI
DEC 9 9 2013
USPTO
PATENT & TRADEMARK OFFICE

323.	Yi, A-K. and Krieg, A. M. (February 1998a). "CpG DNA Rescue from Anti-IgM-Induced WEHI-231 B Lymphoma Apoptosis Via Modulation of I κ B α and I κ B β and Sustained Activation of Nuclear Factor- κ B/c-Rel," <i>J. Immunol.</i> 160(3):1240-1245.
324.	Yi, A-K. and Krieg, A. M. (1998d). "Rapid Induction of Mitogen-Activated Protein Kinases by Immune Stimulatory CpG DNA," <i>J. Immunol.</i> 161(9):4493-4497.
325.	Yi, A-K. et al. (January 1996). "IFN- γ Promotes IL-6 and IgM Secretion in Response to CpG Motifs in Bacterial DNA and Oligodeoxynucleotides," <i>J. Immunol.</i> 156(2):558-564.
326.	Yi, A-K. et al. (1 May 1998b). "CpG Motifs in Bacterial DNA Activate Leukocytes Through the pH-Dependent Generation of Reactive Oxygen Species," <i>J. Immunol.</i> 160(10):4755-4761.
327.	Yi, A-K. et al. (June 1998c). "CpG Oligodeoxyribonucleotides Rescue Mature Spleen B Cells from Spontaneous Apoptosis and Promote Cell Cycle Entry," <i>J. Immunol.</i> 160(12):5898-5906.
328.	Yu, D. et al. (2000). "Accessible 5'-End of CpG-Containing Phosphorothioate Oligodeoxynucleotides is Essential for Immunostimulatory Activity," <i>Bioorg. Med. Chem. Lett.</i> 10(23):2585-2588.
329.	Yu, D. et al. (2003). "Requirement of Nucleobase Proximal to CpG Dinucleotide for Immunostimulatory Activity of Synthetic," <i>Bioorg. Med. Chem.</i> 11(3):459-464.
330.	Yu, D. et al. (2002). "Potent CpG Oligonucleotides Containing Phosphodiester Linkages: In Vitro and In Vivo Immunostimulatory Properties," <i>Biochem and Biophys. Res. Comm.</i> 297(1):83-90.
331.	Yu, D. et al. (2002). "'Immunomers' -Novel 3'-3' -Linked CpG Oligonucleotides as Potent Immunomodulatory Agents," <i>Nucleic Acids Res.</i> 30(20):4460-4469.
332.	Yu, D. et al. (2002). "Design, Synthesis, and Immunostimulatory Properties of CpG DNAs Containing Alkyl-Linker Substitutions: Role of Nucleosides in the Flanking Sequences," <i>J. of Med. Chem.</i> 45(20):4540-4548.
333.	Zhao, Q. et al. (1996). "Effect of Different Chemically Modified Oligodeoxynucleotides on Immune Stimulation," <i>Biochem. Pharmacol.</i> 51(2):173-182.
334.	Zhao, Q. et al. (December 1999). "Site of Chemical Modifications in CpG Containing Phosphorothioate Oligodeoxynucleotide Modulates its Immunostimulatory Activity," <i>Bioorg. Med. Chem. Lett.</i> 9(24):3453-3458.
335.	Zimmermann, S. et al. (1998). "CpG Oligodeoxynucleotides Trigger Protective and Curative Th1 Responses in Lethal Murine Leishmaniasis," <i>J. Immunol.</i> 160(8):3627-3630.
336.	Zon, G. (1993). "Oligonucleoside Phosphorothioates," Chapter 8 <i>In Protocols for Oligonucleotides and Analogs, Synthesis and Properties</i> , Sudhir Agrawal, ed., Humana Press, Totowa, NJ., pp.165-189.
337.	Zuckermann, R. et al. (1987). "Efficient Methods for Attachment of Thiol Specific Probes to the 3'-Ends of Synthetic Oligodeoxyribonucleotides," <i>Nucleic Acids Res.</i> 15(13):5305-5321.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.